Sanofi Archives

News and Trends 29 Feb 2016

Our Top 5 Articles on Biotech & Rare Disease

Today is Rare Disease Day 2016. Because it is an important field for Biotech, we went back to review some of our best articles on the topic from the Labiotech archives. Here are some of our best – in addition to an overview of 7 Rare diseases and who in Biotech is working on them. Nº […]

February 29, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 11 Feb 2016

Sanofi-Genzyme: Still successful 5 years after the acquisition?

Back in 2011, France’s biggest Pharmaceutical company Sanofi decided to purchase Genzyme Corp. for more than $20 billion, thus becoming the latest global drug giant to acquire a big biotech to foster its R&D pipeline. 5 years later, what’s the situation for Genzyme and Sanofi? So often when a large Pharma acquires a smaller Biotech, […]

February 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Feb 2016

Zika Virus: Who in Biotech is Working to Stop its Spread?

The Zika virus epidemic could infect up to 4 Million people. As a cousin to Dengue Fever, what are the risks? Who in the Biotech and pharma world are working on a vaccine? And what is exactly this virus which has everyone hot and bothered? Literally meaning ‘overgrown‘ in the Luganda language, the Zika Virus name comes from the […]

February 4, 2016 - 4 minutesmins - By Nicolas Sainte-Foie

innate pharma immunooncology biotech cancer orega sanofi

News and Trends 11 Jan 2016

A French Biotech is Monopolising Immuno-Oncology with Big Euro Deals

Marseille’s Innate Pharma is building an Immuno-Oncology Monopoly, deal by deal. Selling to the French Pharma Giant, Sanofi, this 112 employee biotech has used their Sanofi-income to buy up Lyon-based Orega Biotech‘s checkpoint inhibitor program. Sanofi and Innate Pharma will work together on the generation and evaluation of up to two bispecific NK cell engagers, […]

January 11, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 22 Dec 2015

Dutch Organ-on-Chip Biotech Hauls in €1.5M Funding from Pharma Syndicate in Project Against Animal Testing

Mimetas from Leiden (NL) has now been financed to develop an Organ-on-Chip (tissue model) to specifically test Neurotoxicity, as a piece of medtech to help clinical trials move away from Animal testing… Organs-on-Chips are microfluidic tissue models which mimic basic organ-to-organ coupling. Developed with the aim of simulating ADMET testing and drug screening in vitro, […]

December 22, 2015 - 3 minutesmins - By Dani Bancroft

regeneron sanofi praulant odyssey alirocumab cardiac statins

News and Trends 27 Nov 2015

18,000 Patients Enrolled for One of the Most Comprehensive Trials Against Cholesterol

Sanofi & Regeneron have completed enrollment in the global Phase III for Praulent (alirocumab), which is evaluating its potential cardiovascular benefits for patients with acute coronary syndrome (ACS). The ‘Odyssey Outcomes’ Study has enrolled around 18,000 patients for its trial (phwoar), and if it shows positive results could be a huge success for Sanofi and […]

November 27, 2015 - 2 minutesmins - By Dani Bancroft

seasonal influenza universal vaccine sanofi peptcell seek niaid nihr

News and Trends 12 Nov 2015

Sanofi’s COBRA Research to Tackle the Challenge of A Universal Influenza Vaccine for Winter

Sanofi Pasteur is the infectious disease division of the French Giant Sanofi, responsible for producing 1 Billion vaccine doses each year. Now they are looking to ‘evolve’ the vaccine R&D field, adapting their approach to find a broader spectrum defense against seasonal Influenza strains. However, the UK NIHR and PepTCell are also after the same […]

November 12, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Nov 2015

€1.37Bn Deal for Sanofi with Germany’s Fastest Growing mRNA Cancer Biotech

Sanofi is now the latest Biotech lining up to partner with BioNTech from Mainz (Germany), for license of their mRNA Immuno-oncology platform in a€1.37Bn long-term development deal. Novel mRNA targets in Immuno-onology is a top-shelf cancer R&D area, with Germany’s CureVac also attracting another €100M yesterday for their mRNA platform (which targets lung and prostate […]

November 4, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 4 Nov 2015

Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

The Biotech industry relies a lot on partnering and deals. And 2015 has already been an active year. This was the theme of the second keynote conference from BIO-Europe 2015. It gathered four high-level speakers: The roundtable started with a summary of each companies’ activity in deals. Everyone has been busy, but Celgene seemed to […]

November 4, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 12 Oct 2015

Roche dishes out €509M for a Humanized antibody against Rheumatoid Arthritis

Adheron Therapeutics is a small California (US) biotech which has developed a phase I monoclonal antibody (mAb) therapy for inflammatory diseases such as Rheumatoid Arthritis. Using the mAb humanisation platform licensed from Abzena (a life Sciences group from Cambridge, UK), Adheron Therapeutics will now be acquired by Swiss giant Roche for €509M. Abzena, based in […]

October 12, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 28 Sep 2015

Sanofi and Regeneron’s Praluent succeeds at final hurdle with EU authorisation

Regeneron (NY, USA) has finally brought alirocumab (trade name Praluent) to the finish line with collaborator Sanofi, today announcing that the European commission has granted its hypercholesterolemia drug a marketing license for the EU. Having already been approved by the FDA in July, this completes Praluent’s launch into the Western pharma market. New-York based Regeneron […]

September 28, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 16 Sep 2015

Giving new life to Sanofi’s annual €6.2Bn diabetes blockbuster Lantus

Sanofi has announced positive results of its combination drug LixiLan phase III trials for Type 2 diabetes. Constituted from both Lixisenatide and insulin glargine Lantus, LixiLan is developed to tackle type 2 diabetes when both oral medication fails and basal insulin loses its efficacy. Lixisenatide (Lyxumia outside the US) was initially discovered by Zealand […]

September 16, 2015 - 2 minutesmins - By Dani Bancroft

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us